{"formats":[{"id":"adc","name":"Antibody-drug conjugates","route":"/modalities/adc/","file":"/modalities/adc/data.json","engine":"/pipeline/engine/adc/","counts":{"drugs":93,"approved":20,"phase3":43,"trials":305,"companies":58,"papers":44,"ideas":54,"eras":19},"technologies":["adc","bispecific-adc","site-specific-conjugation","topoisomerase-inhibitors","peptide-drug-conjugate","dual-payload-adc","masked-adc","immune-stimulating-adc","degrader-antibody-conjugate","antibody-oligonucleotide-conjugates","adc-payload-neutralizer","adc-supply-chain","adc-cdmo-manufacturing","high-potency-payload-synthesis"]},{"id":"radioligand","name":"Radioligands","route":"/modalities/radioligand/","file":"/modalities/radioligand/data.json","engine":"/pipeline/engine/radioligand/","counts":{"drugs":17,"approved":7,"phase3":8,"trials":10,"companies":15,"papers":3,"ideas":22,"eras":13},"technologies":["radioligand-therapy","lu177-radioligand-therapy","targeted-alpha-therapy","prrt","radioimmunotherapy","radioiodine-therapy","mibg-theranostics","astatine-211-alpha-therapy","radioligand-dosimetry","radionuclide-parp-combination","alpha-nanogenerators","therapy-isotope-supply-chain","actinium-225-supply","research-reactor-isotope-production","cyclotron-isotope-production","radiopharmaceutical-gmp-release","radiopharmacy-network"]},{"id":"car-t","name":"CAR cell therapies","route":"/modalities/car-t/","file":"/modalities/car-t/data.json","engine":"/pipeline/engine/car-t/","counts":{"drugs":36,"approved":14,"phase3":4,"trials":33,"companies":25,"papers":26,"ideas":44,"eras":9},"technologies":["car-t","glioma-car-t","in-vivo-car-t","car-nk-macrophage","stroma-directed-car","car-t-manufacturing-process","apheresis-starting-material","cell-therapy-cold-chain","point-of-care-cell-manufacturing"]},{"id":"tcr-t","name":"TCR-T cell therapies","route":"/modalities/tcr-t/","file":"/modalities/tcr-t/data.json","engine":"/pipeline/engine/tcr-t/","counts":{"drugs":5,"approved":1,"phase3":2,"trials":3,"companies":5,"papers":2,"ideas":8,"eras":3},"technologies":["tcr-t"]},{"id":"bispecific","name":"Bispecific antibodies","route":"/modalities/bispecific/","file":"/modalities/bispecific/data.json","engine":"/pipeline/engine/bispecific/","counts":{"drugs":65,"approved":17,"phase3":26,"trials":207,"companies":43,"papers":19,"ideas":20,"eras":6},"technologies":["bispecific-antibody","t-cell-engager","trispecific-antibodies","nk-cell-engagers"]},{"id":"degrader","name":"Degraders and molecular glues","route":"/modalities/degrader/","file":"/modalities/degrader/data.json","engine":"/pipeline/engine/degrader/","counts":{"drugs":15,"approved":6,"phase3":5,"trials":55,"companies":12,"papers":11,"ideas":18,"eras":9},"technologies":["protac-degrader","celmods","molecular-glue-platforms","degrader-antibody-conjugate"]},{"id":"small-molecule","name":"Small-molecule inhibitors","route":"/modalities/small-molecule/","file":"/modalities/small-molecule/data.json","engine":"/pipeline/engine/small-molecule/","counts":{"drugs":374,"approved":201,"phase3":89,"trials":553,"companies":186,"papers":206,"ideas":87,"eras":33},"technologies":["kinase-inhibitors","parp-inhibitor","cdk46-inhibitor","kras-inhibitors","bcl2-inhibitors","idh-inhibitors","menin-inhibitors","endocrine-therapy","oral-serds","pi3k-akt-mtor-inhibitors","hedgehog-inhibitors","mdm2-inhibitors","her2-tyrosine-kinase-inhibitors","atr-chk1-inhibitors","kat6-inhibitors","lsd1-inhibitors","gamma-secretase-inhibitors","androgen-deprivation","epigenetic-drugs","small-molecule-api-synthesis"]},{"id":"antibody","name":"Naked antibodies","route":"/modalities/antibody/","file":"/modalities/antibody/data.json","engine":"/pipeline/engine/antibody/","counts":{"drugs":149,"approved":61,"phase3":44,"trials":640,"companies":117,"papers":203,"ideas":111,"eras":11},"technologies":["monoclonal-antibody","checkpoint-inhibitor","cd47-blockade","cd40-agonists","monoclonal-antibody-manufacturing"]},{"id":"cytokine","name":"Cytokines","route":"/modalities/cytokine/","file":"/modalities/cytokine/data.json","engine":"/pipeline/engine/cytokine/","counts":{"drugs":13,"approved":9,"phase3":2,"trials":6,"companies":14,"papers":3,"ideas":6,"eras":2},"technologies":["cytokine-therapy","immunocytokines"]},{"id":"vaccine","name":"Cancer vaccines","route":"/modalities/vaccine/","file":"/modalities/vaccine/data.json","engine":"/pipeline/engine/vaccine/","counts":{"drugs":25,"approved":5,"phase3":9,"trials":14,"companies":23,"papers":11,"ideas":24,"eras":11},"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine","dendritic-cell-vaccines","hpv-vaccine","interception-vaccination","bacterial-vector-vaccines","mrna-lnp-manufacturing","plasmid-dna-manufacturing"]},{"id":"oncolytic-virus","name":"Oncolytic viruses","route":"/modalities/oncolytic-virus/","file":"/modalities/oncolytic-virus/data.json","engine":"/pipeline/engine/oncolytic-virus/","counts":{"drugs":8,"approved":3,"phase3":2,"trials":10,"companies":10,"papers":0,"ideas":3,"eras":1},"technologies":["oncolytic-virus"]},{"id":"cell-therapy","name":"Other cell therapies","route":"/modalities/cell-therapy/","file":"/modalities/cell-therapy/data.json","engine":"/pipeline/engine/cell-therapy/","counts":{"drugs":10,"approved":6,"phase3":1,"trials":12,"companies":9,"papers":9,"ideas":16,"eras":5},"technologies":["til-therapy","nk-cell-therapy","virus-specific-t-cells","gamma-delta-t-cell-therapy","allogeneic-cell-therapy","allogeneic-cell-banks","allogeneic-cell-banking","allogeneic-hsct"]}],"note":"One hub per format of the open drug engine, assembling what the corpus records about that shape of medicine. CC BY-NC 4.0, attribute Data from OnCo (onco.cc). Not medical advice."}